Artificial organs

• Artificial kidney
• Artificial blood vessels
• Artificial cells

Chronicle

2024: Global Artificial Organ Market Growth to $12.2 Million for the Year

At the end of 2024, the costs of the global artificial organ market reached $12.2 million. More than half of this amount fell on the North American region. Such data are reflected in the Fortune Business Insights review presented at the end of March 2025.

Artificial organs are specialized devices that are implanted or integrated into a patient to replace a natural organ in order to restore a specific function or group of related functions. The study says an aging population combined with the increasing prevalence of chronic diseases such as diabetes, cardiovascular ailments and kidney lesions leads to an increase in organ failure cases. In this regard, the number of transplantation operations is growing rapidly, which, in turn, creates an additional need for artificial organs that can act as a "bridge" in such procedures.

Analysts point to a significant gap between the number of patients suffering from end-stage chronic diseases and available treatment options. Against this background, organizations and medical companies around the world are intensifying research and development work in the field of advanced artificial organs. Technological advances are also driving the industry's expansion. In particular, techniques are actively developing that allow you to create artificial organs that work like real ones. The introduction of such methods into clinical practice will help solve the problems of donor organ deficiency.

The study authors cite high financial costs as the main deterrent. The estimated cost of an artificial heart, including surgical procedures, devices and constant medical supervision, ranges from $100 thousand to $300 thousand per patient in the first year. For example, in January 2021, the European Commission approved the sale of a completely new artificial heart, produced and developed by Carmat, worth about $180 thousand. In addition, there are significant technical difficulties in the design of artificial organs.

By device type, the market is segmented into artificial heart, artificial kidney, artificial lung, etc. In 2024, the lion's share of revenue was provided by the first of the listed sectors. Constructively, the authors of the study distinguish implantable and wearable devices: the first type of products dominate, since they are able to provide long-term support, reducing the need for replacement and repeated operations. In addition, many large developers focus on implantable artificial organs. From a geographical point of view, North America provided the bulk of the revenue in 2024 - $6.6 million against $3.7 million a year earlier: the dominance of the region is explained by significant research and development costs from pharmaceutical and biotechnology companies in combination with active clinical trials. Globally, the list of leading market players includes:

• Carmat;
• SynCardia Systems;
• BiVacor;
• Awak Technologies;
• Wearable Artificial Organs.

In 2025, spending on artificial organs worldwide is expected to rise to $18.9 million. Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be 32.1%. As a result, costs globally could increase to $132.7 million by 2032.^[1]

Notes